NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Indivior and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 9, 2024, Indivior issued a press release “announc[ing] a business update encompassing [its] for Q2 and FY 2024 financial performance[.]” Among other items, Indivior lowered its fiscal year 2024 financial outlook, citing, among other things, sales headwinds related to Sublocate, a prescription drug indicated for opioid use disorder. Indivior also announced the decision to discontinue its schizophrenia therapy Perseris, a move that the Company said would reduce headcount by approximately 130 employees.
On this news, Indivior’s stock price fell $5.15 per share, or 33.57%, to close at $10.19 per share on July 9, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
